{
    "id": 23139,
    "fullName": "CUL1 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "CUL1-BRAF results from the fusion of CUL1 and BRAF (PMID: 26324360), and has not been biochemically characterized, however, due to the effects of other BRAF fusions that result in loss of the BRAF CR1 domain and retention of the protein kinase domain (PMID: 23890088, PMID: 12781369), is predicted to result in a gain of function. CUL1-BRAF has been identified in melanoma (PMID: 31618628) and low-grade serous ovarian cancer (PMID: 26324360).",
            "references": [
                {
                    "id": 3413,
                    "pubMedId": 23890088,
                    "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                },
                {
                    "id": 16509,
                    "pubMedId": 31618628,
                    "title": "Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31618628"
                },
                {
                    "id": 5860,
                    "pubMedId": 26324360,
                    "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324360"
                },
                {
                    "id": 14743,
                    "pubMedId": 12781369,
                    "title": "Raf proteins and cancer: B-Raf is identified as a mutational target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12781369"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8454,
        "geneSymbol": "CUL1",
        "terms": [
            "CUL1"
        ]
    },
    "variant": "CUL1 - BRAF",
    "createDate": "06/11/2016",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 16189,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with recurrent serous ovarian cancer harboring a BRAF-CUL1 fusion was treated with combined Taxol (paclitaxel) and Mektovi (binimetinib) therapy for 7 months, and achieved a complete response that lasted an additional 25 months followed by disease progression (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 23814,
                "profileName": "CUL1 - BRAF"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6845,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with CUL1-BRAF positive serous ovarian cancer experienced a sustained complete remission when treated with Selumetinib (AZD6244) and Taxol (paclitaxel), with remission lasting off therapy and for greater than 18 months of follow up (PMID: 26324360).",
            "molecularProfile": {
                "id": 23814,
                "profileName": "CUL1 - BRAF"
            },
            "therapy": {
                "id": 4282,
                "therapyName": "Paclitaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5860,
                    "pubMedId": 26324360,
                    "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23814,
            "profileName": "CUL1 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}